According to our (Global Info Research) latest study, the global Straight Tube Thoracic Aortic Stent Graft System market size was valued at US$ 668 million in 2025 and is forecast to a readjusted size of US$ 1034 million by 2032 with a CAGR of 6.4% during review period.
Straight Tube Thoracic Aortic Stent Graft System refers to a catheter-delivered, tube-shaped and non-branched implant system used in thoracic endovascular aortic repair. A complete system comprises a self-expanding covered stent, a dedicated delivery catheter and deployment-control components. The implant typically combines a nitinol or stainless-steel framework with a polyester or expanded polytetrafluoroethylene graft and radiopaque markers. Commercial systems generally cover nominal diameters of approximately 16–46 mm, covered lengths of about 60–260 mm and delivery profiles concentrated around 18–24 Fr, with selected low-profile systems reaching 18 Fr or below. The research scope covers cylindrical, tapered, reverse-tapered and thoracic extension configurations, with or without a proximal bare stent, implanted through a vascular access route into the aortic arch or descending thoracic aorta. Their principal functions are to exclude aneurysms or ruptures, seal dissection entry tears, restore true-lumen flow and reinforce diseased aortic segments. Major indications include thoracic aortic aneurysm, Stanford type B aortic dissection, traumatic thoracic aortic injury, intramural hematoma, penetrating atherosclerotic ulcer and related thoracic aortic lesions.
Key Findings
In 2025, global Straight Tube Thoracic Aortic Stent Graft System production reached approximately 75.71 K Units, with an average global market price of around US$ 8,571 per unit.
Non-branched tube-type systems remain the volume core of TEVAR for descending thoracic aortic disease
Stanford type B dissection and descending thoracic aneurysm are the principal demand-generating indications worldwide
Commercial diameters generally span about 16–46 mm while low-profile delivery systems increasingly reach 18 Fr or below
Market Trends
Product development is shifting from basic aneurysm exclusion toward pathology-specific control, lower procedural trauma and more predictable aortic remodeling. Key upgrades include lower-profile hydrophilic delivery sheaths, staged or controlled deployment, tip-capture mechanisms, repositioning or angulation control, reduced distal radial force, anti-shortening structures and broader tapered configurations for dissection anatomy. Longer grafts and selectively perforated distal sections are being introduced to improve true-lumen expansion while managing spinal-cord perfusion risk. Manufacturers are also optimizing graft porosity, suture durability, radiopaque-marker layouts and proximal sealing structures to reduce bird-beak formation, endoleak and stent-graft-induced new entry. Hospitals increasingly value complete size matrices, immediate emergency inventory, simplified deployment and compatibility with hybrid operating rooms rather than isolated implant specifications. Over the longer term, CTA-based sizing, digital procedural planning, patient-specific simulation, post-market imaging analysis and integration with adjunctive bare stents will become more closely connected with product sales. Straight tube systems will remain the procedural workhorse, while branched and fenestrated devices address anatomies requiring supra-aortic branch preservation.
Market Dynamics
Drivers
Demand is supported by population aging, improved CT detection of aortic disease, expansion of specialist aortic centers and the continuing substitution of open repair with less invasive endovascular treatment in anatomically suitable patients. Clinical guidance from the Society for Vascular Surgery and the Society of Thoracic Surgeons supports TEVAR in descending thoracic aneurysm and complicated type B dissection under appropriate conditions. Lower-profile devices expand eligibility among patients with small, calcified or tortuous access vessels, while better deployment control reduces procedural uncertainty. Demand is also generated by residual or recurrent disease after prior aortic surgery, traumatic injury, penetrating ulcers, intramural hematoma and emergency rupture. Broader reimbursement coverage, increasing physician training and the localization of high-value aortic devices in China and other emerging markets further support unit growth.
Restraints
Adoption remains constrained by demanding anatomy and the need for adequate proximal and distal landing zones. Severe arch angulation, extensive calcification, thrombus, small access arteries, connective-tissue disorders and disease involving major branch vessels can limit the use of standard tube-type systems. Clinical risks include endoleak, migration, retrograde type A dissection, spinal-cord ischemia, stroke, access-vessel injury and distal stent-graft-induced new entry. Patients require lifelong imaging surveillance, adding downstream healthcare costs and making long-term durability evidence important to purchasing decisions. Product development also requires substantial investment in fatigue testing, biocompatibility, sterilization validation, clinical trials and post-market surveillance. In price-controlled markets, declining tender or listing prices may improve access but compress margins and reduce the economic attractiveness of maintaining a large inventory of diameters, lengths and taper combinations.
Opportunities
The largest product opportunities lie in low-profile systems at or below 18 Fr, long-length and large-taper configurations for dissection, low-radial-force distal designs and systems providing accurate staged deployment. Wider diameter and length coverage can reduce the need to combine multiple grafts, potentially lowering procedure time and type III endoleak risk. Emerging-market hospitals need reliable, standardized tube-type systems before adopting more complex branched platforms, creating opportunities for manufacturers with local regulatory, training and service capabilities. Additional value can be captured through CTA planning, emergency inventory programs, proctoring, case support and bundled guidewire, sheath, balloon and adjunctive bare-stent solutions. Localized manufacturing in China, South Korea and other Asian markets can improve price competitiveness, while established suppliers can defend premium positioning through long-term clinical evidence, controlled deployment, full-size portfolios and international regulatory approvals.
Challenges
Manufacturers must balance conformability, sealing force and fixation strength against the risk of aortic-wall injury and new dissection. Small changes in nitinol heat treatment, stent geometry, graft permeability, suture tension or crimping can materially affect fatigue performance and deployment accuracy, creating high process-control requirements. A broad product matrix also increases inventory, validation and expiration-management costs. Regulatory expectations for long-term durability, rare adverse-event detection and post-market surveillance continue to rise, while recalls can quickly disrupt hospital procurement and regional market access. Competitive pressure is intensifying as Chinese manufacturers move from conventional tube grafts toward low-profile, long-segment and dissection-specific products. At the same time, centralized procurement and price-governance policies are narrowing room for distributor markups, forcing manufacturers to improve direct coverage, clinical support and supply-chain efficiency without compromising emergency availability.
Industry Chain Analysis
The upstream segment supplies medical-grade nitinol tubing or wire, stainless steel, woven polyester, ePTFE membranes, platinum-iridium or gold radiopaque markers, sutures, catheter polymers, hydrophilic coatings and sterilization packaging. Midstream manufacturing includes stent laser cutting or wire forming, electropolishing, heat setting, graft weaving or membrane processing, stent-graft sewing or bonding, marker attachment, catheter extrusion, cleanroom assembly and deployment-system integration. Critical validation covers radial force, fatigue, corrosion, graft permeability, tensile strength, dimensional accuracy, delivery and release performance, biocompatibility, sterilization and shelf life. Downstream participants include vascular-surgery, cardiovascular-surgery and interventional departments, tertiary hospitals, regional aortic centers, distributors, imaging-planning teams and reimbursement agencies. Value is created less through raw-material consumption than through implant design, delivery control, clinical evidence, regulatory approval, size-matrix completeness, physician training and dependable emergency supply. Post-implant CTA surveillance and adverse-event reporting feed back into product iteration and risk management, making clinical-service capability an integral part of the industrial chain.
Segment Insights
By graft material, polyester and ePTFE are the principal categories, with selection affecting permeability, thickness, flexibility and sealing behavior. By geometry, the market can be divided into cylindrical, tapered, reverse-tapered and thoracic extension grafts. Cylindrical products serve relatively uniform descending-aortic anatomy, whereas tapered products better match the distal narrowing commonly observed in dissection. Additional useful classifications include proximal bare-stent versus fully covered fixation, standard versus long-length systems, delivery profile of 18 Fr or below, 19–22 Fr and 23 Fr or above, and nominal diameter below 26 mm, 26–34 mm, 35–42 mm and above 42 mm. Tube-type systems remain the largest-volume configuration because they offer broad availability, standardized deployment and extensive use in descending thoracic aneurysm and type B dissection. Product value is migrating toward low-profile access, larger taper ranges, longer coverage and controlled deployment rather than a simple change in implant material. Commercial specifications from GORE, Cook Medical and MicroPort Endovascular illustrate the breadth of diameter, length and delivery options now required.
Downstream Market Opportunities
Stanford type B dissection represents a particularly important unit-demand opportunity in China and parts of Asia, where clinicians require tapered, long-segment, conformable systems with controlled radial force and options for adjunctive distal bare-stent support. Thoracic aneurysm treatment is more prominent among aging populations in North America, Europe and Japan, supporting demand for durable sealing, large-diameter availability and long-term surveillance evidence. Traumatic aortic injury, pseudoaneurysm and rupture are lower-frequency but time-critical applications in which immediate inventory, compact delivery profiles and rapid, predictable deployment are decisive. Penetrating atherosclerotic ulcer and intramural hematoma expand the addressable acute-aortic-syndrome population when intervention is clinically indicated. The principal customers are tertiary hospitals, regional aortic centers and cardiovascular programs equipped with hybrid operating rooms, advanced CTA planning and multidisciplinary teams. Suppliers able to provide full-size emergency inventories, procedural training and rapid case-planning support can gain an advantage beyond the implant itself.
Regional Insights
North America and Europe form the largest established value pool, supported by mature TEVAR adoption, specialist centers, reimbursement systems and long-term clinical evidence for products from Medtronic, W. L. Gore, Terumo Aortic and Cook Medical. Japan is a highly regulated, clinically mature market with demand for conformability and smaller-access solutions, while South Korea maintains a regional manufacturing presence through S&G Biotech. China combines substantial type B dissection demand with rapid domestic substitution led by MicroPort Endovascular, LifeTech Scientific, APT Medical and Beijing Percutek Therapeutics. Pricing pressure is materially stronger in China: the National Healthcare Security Administration reported that 12 domestic and international companies reset thoracic stent-graft terminal listing prices in 2024, with the publicly reported category quotations falling below RMB 80,000. Southeast Asia, Latin America and the Middle East remain import-oriented growth markets where regulatory registration, physician training and distributor capability determine commercial access. Product availability and approved indications vary significantly by country, requiring regional rather than purely global portfolio assessment.
Competitive Landscape Analysis
The global core consists of Medtronic, W. L. Gore & Associates, Terumo Aortic and Cook Medical, which compete through clinical evidence, delivery control, conformability, broad sizing portfolios and global training networks. Artivion participates through the E-vita Thoracic 3G platform in selected markets. The principal Chinese tube-type competitors are MicroPort Endovascular with Hercules and Talos, LifeTech Scientific with Ankura, APT Medical with RescSeal and Beijing Percutek Therapeutics with the Tianyi system; Aortec Medical Technology remains a regional specialist. SB-KAWASUMI’s Najuta provides straight and tapered sizes but is primarily positioned as a semi-custom, frequently fenestrated solution, placing it in the extended rather than core tube-type pool. Shanghai INT Medical Instruments is more directly associated with branched and hybrid aortic solutions, including the acquired or affiliated Hangzhou Endonom platform, and should be treated as an adjacent participant. S&G Biotech and INVAMED add regional competition. Competitive advantage depends on deployment precision, low-profile access, dissection-specific geometry, evidence quality, emergency inventory, regulatory coverage, hospital access and the ability to operate profitably under tightening price controls.
Report Scope
This report is a detailed and comprehensive analysis for global Straight Tube Thoracic Aortic Stent Graft System market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Straight Tube Thoracic Aortic Stent Graft System market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Straight Tube Thoracic Aortic Stent Graft System market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Straight Tube Thoracic Aortic Stent Graft System market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Straight Tube Thoracic Aortic Stent Graft System market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Straight Tube Thoracic Aortic Stent Graft System
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Straight Tube Thoracic Aortic Stent Graft System market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Medtronic, W. L. Gore & Associates, Terumo, Cook Medical, Artivion, SB-KAWASUMI LABORATORIES, MicroPort Endovascular MedTech, APT Medical, LifeTech Scientific Corporation, Beijing Percutek Therapeutics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Straight Tube Thoracic Aortic Stent Graft System market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market Segmentation
Market segment by Type
Polyester
ePTFE
Other
Market segment by Proximal Structure
Covered Stent With Bare Segments
Covered Stent Without Bare Segments
Market segment by Diameter
Diameter<30mm
Diameter 30-40mm
Diameter>40mm
Market segment by Application
Thoracic Aortic Aneurysm
Stanford B-Type Aortic Dissection
Traumatic Injury of Thoracic Aorta
Aortic Intramural Hematoma
Other
Major players covered
Medtronic
W. L. Gore & Associates
Terumo
Cook Medical
Artivion
SB-KAWASUMI LABORATORIES
MicroPort Endovascular MedTech
APT Medical
LifeTech Scientific Corporation
Beijing Percutek Therapeutics
Aortec Medical Technology
Shanghai INT Medical Instruments
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter Outline
Chapter 1, to describe Straight Tube Thoracic Aortic Stent Graft System product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Straight Tube Thoracic Aortic Stent Graft System, with price, sales quantity, revenue, and global market share of Straight Tube Thoracic Aortic Stent Graft System from 2021 to 2026.
Chapter 3, the Straight Tube Thoracic Aortic Stent Graft System competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Straight Tube Thoracic Aortic Stent Graft System breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Straight Tube Thoracic Aortic Stent Graft System market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Straight Tube Thoracic Aortic Stent Graft System.
Chapter 14 and 15, to describe Straight Tube Thoracic Aortic Stent Graft System sales channel, distributors, customers, research findings and conclusion.
Summary:
Get latest Market Research Reports on Medtronic
W. L. Gore & Associates
Terumo
Cook Medical
Artivion
SB-KAWASUMI LABORATORIES
MicroPort Endovascular MedTech
APT Medical
LifeTech Scientific Corporation
Beijing Percutek Therapeutics
Aortec Medical Technology
Shangh. Industry analysis & Market Report on Medtronic
W. L. Gore & Associates
Terumo
Cook Medical
Artivion
SB-KAWASUMI LABORATORIES
MicroPort Endovascular MedTech
APT Medical
LifeTech Scientific Corporation
Beijing Percutek Therapeutics
Aortec Medical Technology
Shangh is a syndicated market report, published as Global Straight Tube Thoracic Aortic Stent Graft System Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Medtronic
W. L. Gore & Associates
Terumo
Cook Medical
Artivion
SB-KAWASUMI LABORATORIES
MicroPort Endovascular MedTech
APT Medical
LifeTech Scientific Corporation
Beijing Percutek Therapeutics
Aortec Medical Technology
Shangh market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.